|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ITGB2 |
Gene summary for ITGB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ITGB2 | Gene ID | 3689 |
| Gene name | integrin subunit beta 2 | |
| Gene Alias | CD18 | |
| Cytomap | 21q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P05107 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3689 | ITGB2 | CA_HPV_1 | Human | Cervix | CC | 4.11e-02 | 4.40e-01 | 0.0264 |
| 3689 | ITGB2 | N_HPV_2 | Human | Cervix | N_HPV | 8.15e-04 | 3.74e-01 | -0.0131 |
| 3689 | ITGB2 | CCI_1 | Human | Cervix | CC | 1.38e-04 | -5.07e-01 | 0.528 |
| 3689 | ITGB2 | CCI_3 | Human | Cervix | CC | 1.19e-06 | -5.07e-01 | 0.516 |
| 3689 | ITGB2 | CCII_1 | Human | Cervix | CC | 8.01e-10 | -5.07e-01 | 0.3249 |
| 3689 | ITGB2 | Tumor | Human | Cervix | CC | 6.51e-23 | -5.07e-01 | 0.1241 |
| 3689 | ITGB2 | sample1 | Human | Cervix | CC | 5.87e-08 | -5.07e-01 | 0.0959 |
| 3689 | ITGB2 | sample3 | Human | Cervix | CC | 1.12e-16 | -4.98e-01 | 0.1387 |
| 3689 | ITGB2 | H2 | Human | Cervix | HSIL_HPV | 3.04e-15 | -4.67e-01 | 0.0632 |
| 3689 | ITGB2 | T1 | Human | Cervix | CC | 1.45e-13 | -4.78e-01 | 0.0918 |
| 3689 | ITGB2 | T3 | Human | Cervix | CC | 1.06e-17 | -5.02e-01 | 0.1389 |
| 3689 | ITGB2 | C21 | Human | Oral cavity | OSCC | 3.86e-20 | 6.40e-01 | 0.2678 |
| 3689 | ITGB2 | C46 | Human | Oral cavity | OSCC | 1.37e-06 | 2.03e-01 | 0.1673 |
| 3689 | ITGB2 | C57 | Human | Oral cavity | OSCC | 3.43e-02 | 1.38e-01 | 0.1679 |
| 3689 | ITGB2 | C06 | Human | Oral cavity | OSCC | 1.68e-06 | 7.28e-01 | 0.2699 |
| 3689 | ITGB2 | C08 | Human | Oral cavity | OSCC | 3.66e-04 | 3.65e-01 | 0.1919 |
| 3689 | ITGB2 | C09 | Human | Oral cavity | OSCC | 7.28e-35 | 1.25e+00 | 0.1431 |
| 3689 | ITGB2 | LN22 | Human | Oral cavity | OSCC | 1.23e-03 | 5.22e-01 | 0.1733 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
| GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
| GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
| GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
| GO:00975298 | Cervix | CC | myeloid leukocyte migration | 56/2311 | 220/18723 | 7.21e-08 | 4.15e-06 | 56 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00072295 | Cervix | CC | integrin-mediated signaling pathway | 34/2311 | 107/18723 | 1.01e-07 | 5.25e-06 | 34 |
| GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
| GO:00716218 | Cervix | CC | granulocyte chemotaxis | 37/2311 | 125/18723 | 2.16e-07 | 9.56e-06 | 37 |
| GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
| GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
| GO:00975308 | Cervix | CC | granulocyte migration | 39/2311 | 148/18723 | 2.67e-06 | 7.87e-05 | 39 |
| GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0541620 | Cervix | CC | Viral myocarditis | 27/1267 | 60/8465 | 2.43e-08 | 3.57e-07 | 2.11e-07 | 27 |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
| hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
| hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
| hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0513416 | Cervix | CC | Legionellosis | 20/1267 | 57/8465 | 1.29e-04 | 8.19e-04 | 4.85e-04 | 20 |
| hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
| hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
| hsa0532314 | Cervix | CC | Rheumatoid arthritis | 27/1267 | 93/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 27 |
| hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
| hsa051337 | Cervix | CC | Pertussis | 21/1267 | 76/8465 | 3.08e-03 | 1.19e-02 | 7.03e-03 | 21 |
| hsa0514014 | Cervix | CC | Leishmaniasis | 21/1267 | 77/8465 | 3.65e-03 | 1.34e-02 | 7.91e-03 | 21 |
| hsa045147 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa05416110 | Cervix | CC | Viral myocarditis | 27/1267 | 60/8465 | 2.43e-08 | 3.57e-07 | 2.11e-07 | 27 |
| hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
| hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
| hsa04670110 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
| hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | ADJ |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | ADJ |
| ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Breast | ADJ |
| ITGB2 | ICAM1 | ITGB2_ICAM1 | ITGB2 | Breast | ADJ |
| ITGB2 | ICAM2 | ITGB2_ICAM2 | ITGB2 | Breast | ADJ |
| F11R | ITGAL_ITGB2 | JAM1_ITGAL_ITGB2 | JAM | Breast | ADJ |
| C3 | ITGAM_ITGB2 | C3_ITGAM_ITGB2 | COMPLEMENT | Breast | DCIS |
| C3 | ITGAX_ITGB2 | C3_ITGAX_ITGB2 | COMPLEMENT | Breast | DCIS |
| ITGB2 | CD226 | ITGB2_CD226 | ITGB2 | Breast | DCIS |
| ITGB2 | ICAM1 | ITGB2_ICAM1 | ITGB2 | Breast | DCIS |
| ITGB2 | ICAM2 | ITGB2_ICAM2 | ITGB2 | Breast | DCIS |
| ICAM1 | ITGAX_ITGB2 | ICAM1_ITGAX_ITGB2 | ICAM | Breast | DCIS |
| ICAM1 | ITGAL_ITGB2 | ICAM1_ITGAL_ITGB2 | ICAM | Breast | DCIS |
| ICAM2 | ITGAL_ITGB2 | ICAM2_ITGAL_ITGB2 | ICAM | Breast | DCIS |
| ICAM1 | ITGAM_ITGB2 | ICAM1_ITGAM_ITGB2 | ICAM | Breast | DCIS |
| ICAM2 | ITGAM_ITGB2 | ICAM2_ITGAM_ITGB2 | ICAM | Breast | DCIS |
| THY1 | ITGAM_ITGB2 | THY1_ITGAM_ITGB2 | THY1 | Breast | DCIS |
| THY1 | ITGAX_ITGB2 | THY1_ITGAX_ITGB2 | THY1 | Breast | DCIS |
| CD40LG | ITGAM_ITGB2 | CD40LG_ITGAM_ITGB2 | CD40 | Breast | DCIS |
| FCER2 | ITGAM_ITGB2 | FCER2A_ITGAM_ITGB2 | CD23 | Breast | DCIS |
| Page: 1 2 3 4 5 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ITGB2 | SNV | Missense_Mutation | c.317A>G | p.Tyr106Cys | p.Y106C | P05107 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ITGB2 | SNV | Missense_Mutation | novel | c.1880N>T | p.Ser627Phe | p.S627F | P05107 | protein_coding | tolerated(0.13) | benign(0.029) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| ITGB2 | SNV | Missense_Mutation | rs202025124 | c.1759N>T | p.Arg587Cys | p.R587C | P05107 | protein_coding | deleterious(0.01) | possibly_damaging(0.64) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ITGB2 | SNV | Missense_Mutation | rs745524920 | c.1499N>G | p.Asp500Gly | p.D500G | P05107 | protein_coding | deleterious(0.01) | possibly_damaging(0.842) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ITGB2 | SNV | Missense_Mutation | rs374031101 | c.112G>A | p.Glu38Lys | p.E38K | P05107 | protein_coding | tolerated(0.3) | benign(0.012) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| ITGB2 | SNV | Missense_Mutation | c.1609N>A | p.Asp537Asn | p.D537N | P05107 | protein_coding | deleterious(0.04) | benign(0.199) | TCGA-D8-A1JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ITGB2 | SNV | Missense_Mutation | rs764061135 | c.1571N>A | p.Val524Asp | p.V524D | P05107 | protein_coding | tolerated(0.69) | benign(0.001) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
| ITGB2 | SNV | Missense_Mutation | novel | c.1243G>A | p.Val415Ile | p.V415I | P05107 | protein_coding | tolerated(0.2) | possibly_damaging(0.494) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ITGB2 | insertion | Nonsense_Mutation | novel | c.1719_1720insTCTCTGTACAAACCAGTTGTAGGAATGGTAGAAATCCATCCACACTAAAA | p.Gln574SerfsTer16 | p.Q574Sfs*16 | P05107 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ITGB2 | SNV | Missense_Mutation | rs754683051 | c.1402N>A | p.Gly468Ser | p.G468S | P05107 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | LAK CELL | 7947458,8381564,1683349 | ||
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | ETHANOL | ALCOHOL | 8803617 | |
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | RETINOIC ACID | 12485937,11426618 | ||
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | SALINE | SODIUM CHLORIDE | 12688543 | |
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | OPIOIDS | 10232386 | ||
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109332 | MLNM-2201 | |
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | ANTI-CD3 ANTIBODY | 7517362 | ||
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | CYCLOOXYGENASE INHIBITOR | 2054945 | ||
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | INDOMETHACIN | INDOMETHACIN | 11950807 | |
| 3689 | ITGB2 | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | RANTES | 9174593 |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |